CEBe033-A-3

SA001 Shank3 Hetero2

General

Cell Line

hPSCreg name CEBe033-A-3
Cite as:
CEBe033-A-3 (RRID:CVCL_C9YZ)
Alternative name(s)
SA001 Shank3 Hetero2
Cell line type Human embryonic stem cell (hESC)
Similar lines
CEBe033-A-2
(SA001 Shank3 hetero1)
CEBe033-A-4
(SA001 Shank3 Hetero3)
CEBe033-A-5
(SA001 Shank3 Homo1)
CEBe033-A-6
(SA001 Shank3 Homo2)
CEBe033-A-7
(SA001 Shank3 Homo3)
CEBe033-A
(SA001)
CEBe033-A-11
(SA001_WT_HGPRT_2)
CEBe033-A-1
(GBA1_hESC_GBA#1-/-_10.18.11)
CEBe033-A-8
(SA001_KO_HGPRT_1)
CEBe033-A-9
(SA001_KO_HGPRT_2)
CEBe033-A-10
(SA001_WT_HGPRT_1)
Last update 21st April 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institut from Stem cell Therapy and Exploration of Monogenic diseases (ISTEM)

External Databases

BioSamples SAMEA112903631
Cellosaurus CVCL_C9YZ
Wikidata Q123030887

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Normal 46 XY
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104132810

Ethics

Also have a look at the ethics information for the parental line CEBe033-A .
Is there an MTA available for the cell line? Yes
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? Yes
Constraints for use or distribution Work with human embryonic stem cells requires prior approval by local ethics committees.

hESC Derivation

The source cell information can be found in the parental cell line CEBe033-A.

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Mechanically
CO2 Concentration 5 %
Medium Other medium:
Base medium: StemMacs IPS-Brew XF
Main protein source:
Serum concentration: %
Supplements
StemMacs IPS-Brew XF supp 10 ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-4
Yes
NANOG
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
FOXA2
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes
PAX6
Yes

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 87
Karyotyping method: Spectral karyotyping

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
SNP typing array
No mutations

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Chromosome 22q13.3 Deletion Syndrome
  • Phelan-McDermid Syndrome
  • PHMDS
Genetic modifications
Shank3 (target)
Gene knock-out
22q13.33
targeted deletion into exon 19 of one allele
CRISPR-associated (CRISPR/Cas) System